Drug Profile
RECCE 327
Alternative Names: R 327; RECCE-327Latest Information Update: 08 Apr 2024
Price :
$50
*
At a glance
- Originator Recce Pharmaceuticals
- Developer Path BioAnalytics; Recce Pharmaceuticals
- Class Anti-infectives; Antibacterials; Antivirals; Foot disorder therapies; Polymers; Skin disorder therapies
- Mechanism of Action Bacterial protein inhibitors; Cell wall modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Burn infections; Diabetic foot ulcer; Urinary tract infections
- Phase I Bacterial infections
- Preclinical Clostridium infections; COVID 2019 infections; Influenza virus infections; Sepsis; Streptococcal infections
Most Recent Events
- 04 Apr 2024 Recce Pharmaceuticals has patent protection for R 327 in Israel
- 07 Feb 2024 Recce Pharmaceuticals signs a Memorandum of Understanding (MoU) with PT Etana Biotechnologies Indonesia for the clinical development of RECCE 327 in Indonesia
- 23 Jan 2024 Efficacy and adverse events data from a phase-I/II clinical trials in Diabetic foot ulcer released by Recce Pharmaceuticals